Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication

Table 1 Baseline characteristics of patients enrolled in the study

Characteristics	All patients (n = 303)	With HCC development (n = 8)	Without HCC development (n = 295)	P value
Age, yr	57 (20-85)	62 (49-71)	57 (20-85)	0.1982
Males	182 (60.0)	6 (75.0)	176 (59.7)	0.4843
BMI (kg/m2)	23.3 (15.3-39.5)	23.8 (20.2-26.5)	23.4 (15.3-39.5)	0.8602
Habitual drinker	75 (24.8)	2 (25.0)	73 (24.7)	1.0003
Diabetes mellitus1	25 (8.3)	3 (37.5)	22 (7.5)	0.0193
HCV-RNA (logIU/mL)1	6.2 (1.2-7.6)	5.7 (5.0-6.7)	6.2 (1.2-7.6)	0.2462
HCV genotype 1	152 (50.2)	6 (75.0)	146 (49.5)	0.2833
Stage of fibrosis F3-F4	47 (15.5)	6 (75.0)	41 (13.9)	< 0.0013
Grade of inflammation A2-A3	208 (68.6)	8 (100.0)	200 (67.8)	0.0603
Albumin (g/dL)	4.2 (3.3-4.8)	3.9 (3.3-4.4)	4.2 (3.3-4.7)	0.0322
ALT (IU/L)	52 (11-699)	146 (31-209)	52 (11-699)	0.0172
Platelet count (× 104/μL)	17.5 (5.6-39.6)	10.3 (7.9-19.3)	17.6 (5.6-31.9)	0.0062
GGT (IU/L)	37 (9-517)	66 (28-161)	36 (9-517)	0.0532
AFP (ng/mL)1	5 (1-1380)	11 (5-870)	5 (1-1380)	0.0022
PI use	43 (14.2)	1 (12.5)	42 (14.2)	1.0002

¹Data not available for all patients;

²Mann Whitney-U test;

³χ² test. Data are expressed as medians (range) or numbers (%). P values are for comparisons between patients with and without HCC development. AFP: α-fetoprotein; ALT: Alanine aminotransferase; BMI: Body mass index; GGT: γ-glutamyl transpeptidase; HCV: Hepatitis C virus; PI: Protease inhibitor.